A concern remains for the possibility of resistance since in response to the unusually high levels of plasma cell-niche cytokines in SLE patients, the auto-antibody production is dependent on JAK/STAT3 activation such that this process can be abrogated by inhibition of this pathway by the JAK inhibitor, ruxolitinib (23). Here, STAT3 is linked to systemic lupus erythematosus.